Effect of steroids on brain lipocortin immunoreactivity.
LCT-1, LCT-2 and LCT-5 were assessed in uninjured rats and rats subjected to a cortical freezing injury or middle cerebral artery (MCA) occlusion. Apart from animals receiving no treatment, other uninjured or injured animals received methylprednisolone (2 or 30 mg/kg) or the 21-aminosteroid U-74389F (10 mg/kg) one day and 2 hours before killing. The animals were killed by decapitation 1 hour after the freezing injury or the MCA occlusion and the area containing the lesion was removed and frozen in Freon. Frozen sections were treated with rabbit polyclonal anti-LCT antibody; binding of antibody was visualized by horseradish peroxidase-conjugated swine antirabbit antibody. Without steroid pretreatment, in the uninjured brain LCT immunoreactivity was absent in the greater part of the brain, except in sporadic microglia. In steroid-pretreated animals and in the freezing lesion of both pretreated and untreated animals there was extensive immunostaining; in the freezing lesion it may be due to passage of systemic LCT across the impaired blood-brain barrier in the lesion. The cellular elements showing immunostaining were meningeal cells, neurons, ependyma, choroid plexus, oligodendroglia and capillary endothelium. It implies that also in the brain the steroid effect is consistent with LCT formation.
Go
K G
KG
Department of Neurosurgery, University of Groningen, The Netherlands.
Zuiderveen
F
F
De Ley
L
L
Ter Haar
J G
JG
Parente
L
L
Solito
E
E
Molenaar
W M
WM
D000818:Animals; D017305:Annexin A1 / Q000378:metabolism; D017306:Annexin A2 / Q000378:metabolism; D017304:Annexin A5 / Q000378:metabolism; D017302:Annexins / Q000378:metabolism*; D000975:Antioxidants / Q000494:pharmacology*; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D001929:Brain Edema / Q000473:pathology*; D001930:Brain Injuries / Q000473:pathology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D002544:Cerebral Infarction / Q000473:pathology*; D007124:Immunoenzyme Techniques; D008775:Methylprednisolone / Q000494:pharmacology*; D017628:Microglia / Q000187:drug effects / Q000473:pathology; D009457:Neuroglia / Q000187:drug effects / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D011281:Pregnatrienes / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D017305:Annexin A1; D017306:Annexin A2; D017304:Annexin A5; D017302:Annexins; D000975:Antioxidants; D011281:Pregnatrienes; C074965:U 74389F; D008775:Methylprednisolone